MedTrace Logo

Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children

NCT00408395 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 281

Last updated 2016-12-01

No results posted yet for this study

Summary

This is a study of the safety and immunogenicity of three commercially available influenza vaccines in children.

Conditions

Interventions

BIOLOGICAL

Influenza vaccine

Seasonal Influenza Vaccine

Sponsors & Collaborators

  • Novartis Vaccines

    lead INDUSTRY

Principal Investigators

  • Novartis Vaccines (formerly Chiron Vaccines) · Novartis

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
35 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00408395 on ClinicalTrials.gov